Due to their outstanding clinical effectiveness, the Food and Drug Administration (FDA) and European Medicines Agency (EMA) have approved four CD19 CAR-T cell products to treat patients ≤25 years old with r/r B-ALL (Kymriah), adult patients with r/r B-ALL (Tecartus), patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) (Kymriah, Yescarta and Breyanzi), patients with relapsed or refractory mantle-cell lymphoma (r/r MCL) (Tecartus) and patients with relapsed and refractory follicular lymphoma (Kymriah) (4–8). Here, CD19 is linked to precursor B-cell acute lymphoblastic leukemia.